These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9819131)

  • 1. The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice.
    Clinchy B; Vitetta ES
    J Immunol Methods; 1998 Sep; 218(1-2):141-53. PubMed ID: 9819131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice.
    Coles RE; Boyle TJ; DiMaio JM; Berend KR; Via DF; Lyerly HK
    Ann Surg Oncol; 1994 Sep; 1(5):405-10. PubMed ID: 7531601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
    Baiocchi RA; Caligiuri MA
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
    Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
    J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.
    Dierksheide JE; Baiocchi RA; Ferketich AK; Roychowdhury S; Pelletier RP; Eisenbeis CF; Caligiuri MA; VanBuskirk AM
    Blood; 2005 Feb; 105(4):1558-65. PubMed ID: 15498860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.
    Baiocchi RA; Ward JS; Carrodeguas L; Eisenbeis CF; Peng R; Roychowdhury S; Vourganti S; Sekula T; O'Brien M; Moeschberger M; Caligiuri MA
    J Clin Invest; 2001 Sep; 108(6):887-94. PubMed ID: 11560958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine-tuning the EBV+ hu-PBL-SCID xenogeneic chimera model using in vivo superinfection.
    Kvell K; Balogh P; Németh P
    Pathol Oncol Res; 2000; 6(4):280-6. PubMed ID: 11173661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model.
    Kohn FR; Fishwild DM; Kung AH
    Int J Immunopharmacol; 1993 Aug; 15(6):695-709. PubMed ID: 7691766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.
    Boyle TJ; Tamburini M; Berend KR; Kizilbash AM; Borowitz MJ; Lyerly HK
    Surgery; 1992 Aug; 112(2):378-86. PubMed ID: 1322566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
    Rowe M; Young LS; Crocker J; Stokes H; Henderson S; Rickinson AB
    J Exp Med; 1991 Jan; 173(1):147-58. PubMed ID: 1845872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein-Barr virus-associated lymphomas.
    Zhang Y; Peng X; Tang Y; Gan X; Wang C; Xie L; Xie X; Gan R; Wu Y
    J Med Virol; 2016 Oct; 88(10):1804-13. PubMed ID: 26991077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of hu-PBL/SCID chimeras and development of EBV-related lymphomas.
    Gan RL; Lan K; Yin ZH; Wang LJ; Song Y; Yao KT
    Chin Med Sci J; 2005 Mar; 20(1):16-22. PubMed ID: 15844306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10.
    Baiocchi RA; Ross ME; Tan JC; Chou CC; Sullivan L; Haldar S; Monne M; Seiden MV; Narula SK; Sklar J
    Blood; 1995 Feb; 85(4):1063-74. PubMed ID: 7849294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice.
    Abedi MR; Linde A; Christensson B; Mackett M; Hammarström L; Smith CI
    Int J Cancer; 1997 May; 71(4):624-9. PubMed ID: 9178818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans.
    Purtilo DT; Falk K; Pirruccello SJ; Nakamine H; Kleveland K; Davis JR; Okano M; Taguchi Y; Sanger WG; Beisel KW
    Int J Cancer; 1991 Feb; 47(4):510-7. PubMed ID: 1847355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.